Seastar Medical Holding Corporation (ICU) has disclosed a new risk, in the Supply Chain category.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Seastar Medical Holding Corporation recently ended its exclusive distribution agreement with Nuwellis and has decided to self-commercialize its FDA-approved SCD-PED product, known as QUELIMMUNE. This strategic shift poses a significant risk due to the company’s lack of experience in sales and distribution, which could result in performance not meeting investor expectations. If Seastar Medical fails to establish effective internal sales and distribution capabilities, it may struggle to generate adequate sales for QUELIMMUNE, potentially impacting its business operations and financial results negatively.
The average ICU stock price target is $18.00, implying 818.37% upside potential.
To learn more about Seastar Medical Holding Corporation’s risk factors, click here.
